The Caveolin-1 connection to cell death and survival

Current Molecular Medicine

Volumn 13, Issue 2, 2013, Pages 266-281

  Quest, A F G ^a   Lobos Gonzalez L ^a   Nunez S ^a,c   Sanhueza, C ^a   Fernandez J G ^a,b   Aguirre, A ^a   Rodriguez D ^a   Leyton, L ^a   Torres, V ^a  

^a UNIVERSITY OF CHILE   (Chile)

^b HOSPITAL CLÍNICO UNIVERSIDAD DE CHILE   (Chile)

^c UNIVERSIDAD DE TALCA   (Chile)

Author keywords

Caveolin 1; Cell death; Metastasis; Multi drug resistance; Proliferation; Tumor suppression

Indexed keywords

EID: 84874865781     PISSN: 15665240     EISSN: 18755666     Source Type: Journal    
DOI: 10.2174/156652413804810745     Document Type: Article

References (150)

1. Anderson RG. The caveolae membrane system. Annu Rev Biochem 1998; 67: 199-225.
2. Tang Z, Scherer PE, Okamoto T, et al. Molecular cloning of Caveolin-3, a novel member of the Caveolin gene family expressed predominantly in muscle. J Biol Chem 1996; 271(4): 2255-61.
3. Okamoto T, Schlegel A, Scherer PE, Lisanti MP. Caveolins, a family of scaffolding proteins for organizing preassembled signaling complexes at the plasma membrane. J Biol Chem 1998; 273(10): 5419-22.
4. Drab M, Verkade P, Elger M, et al. Loss of caveolae, vascular dysfunction, and pulmonary defects in Caveolin-1 gene-disrupted mice. Science 2001; 293(5539): 2449-52.
5. Razani B, Engelman JA, Wang XB, et al. Caveolin-1 null mice are viable but show evidence of hyperproliferative and vascular abnormalities. J Biol Chem 2001; 276(41): 38121-38.
6. Liu L, Pilch PF. A critical role of cavin (polymerase I and transcript release factor) in caveolae formation and organization. J Biol Chem 2008; 283(7): 4314-22.
7. Hill MM, Bastiani M, Luetterforst R, et al. PTRF-Cavin, a conserved cytoplasmic protein required for caveola formation and function. Cell 2008; 132(1): 113-24.
8. McMahon KA, Zajicek H, Li WP, et al. SRBC/cavin-3 is a Caveolin adapter protein that regulates caveolae function. EMBO J 2009; 28(8): 1001-15.
9. Hansen CG, Bright NA, Howard G, Nichols BJ. SDPR induces membrane curvature and functions in the formation of caveolae. Nat Cell Biol 2009; 11(7): 807-14.
10. Lajoie P, Goetz JG, Dennis JW, Nabi IR. Lattices, rafts, and scaffolds: domain regulation of receptor signaling at the plasma membrane. J Cell Biol 2009; 185(3): 381-5.
11. Quest AF, Gutierrez-Pajares JL, Torres VA. Caveolin-1: an ambiguous partner in cell signalling and cancer. J Cell Mol Med 2008; 12(4): 1130-50.
12. Dietzen DJ, Hastings WR, Lublin DM. Caveolin is palmitoylated on multiple cysteine residues. Palmitoylation is not necessary for localization of Caveolin to caveolae. J Biol Chem 1995; 270(12): 6838-42.
13. Monier S, Dietzen DJ, Hastings WR, Lublin DM, Kurzchalia TV. Oligomerization of VIP21-Caveolin in vitro is stabilized by long chain fatty acylation or cholesterol. FEBS Lett 1996; 388(2-3): 143-9.
14. Sotgia F, Lee JK, Das K, et al. Caveolin-3 directly interacts with the C-terminal tail of beta -dystroglycan. Identification of a central WW-like domain within Caveolin family members. J Biol Chem 2000; 275(48): 38048-58.
15. Bender F, Montoya M, Monardes V, Leyton L, Quest AF. Caveolae and caveolae-like membrane domains in cellular signaling and disease: identification of downstream targets for the tumor suppressor protein Caveolin-1. Biol Res 2002; 35(2): 151-67.
16. Kogo H, Aiba T, Fujimoto T. Cell type-specific occurrence of Caveolin-1alpha and -1beta in the lung caused by expression of distinct mRNAs. J Biol Chem 2004; 279(24): 25574-81.
17. Park DS, Cohen AW, Frank PG, et al. Caveolin-1 null (-/-) mice show dramatic reductions in life span. Biochemistry 2003; 42(51): 15124-31.
18. Fernandez MA, Albor C, Ingelmo-Torres M, et al. Caveolin-1 is essential for liver regeneration. Science 2006; 313(5793): 1628-32.
19. Goetz JG, Lajoie P, Wiseman SM, Nabi IR. Caveolin-1 in tumor progression: the good, the bad and the ugly. Cancer Metastasis Rev 2008; 27(4): 715-35.
20. Parton RG, Hanzal-Bayer M, Hancock JF. Biogenesis of caveolae: a structural model for Caveolin-induced domain formation. J Cell Sci 2006; 119(Pt 5): 787-96.
21. Parton RG, Howes MT. Revisiting Caveolin trafficking: the end of the caveosome. J Cell Biol; 191(3): 439-41.
22. Hayer A, Stoeber M, Ritz D, Engel S, Meyer HH, Helenius A. Caveolin-1 is ubiquitinated and targeted to intralumenal vesicles in endolysosomes for degradation. J Cell Biol 2010; 191(3): 615-29.
23. Glenney JR, Jr. Tyrosine phosphorylation of a 22-kDa protein is correlated with transformation by Rous sarcoma virus. J Biol Chem 1989; 264(34): 20163-6.
24. Glenney JR, Jr., Zokas L. Novel tyrosine kinase substrates from Rous sarcoma virus-transformed cells are present in the membrane skeleton. J Cell Biol 1989; 108(6): 2401-8.
25. Glenney JR, Jr., Soppet D. Sequence and expression of Caveolin, a protein component of caveolae plasma membrane domains phosphorylated on tyrosine in Rous sarcoma virus-transformed fibroblasts. Proc Natl Acad Sci USA 1992; 89(21): 10517-21.
26. Koleske AJ, Baltimore D, Lisanti MP. Reduction of Caveolin and caveolae in oncogenically transformed cells. Proc Natl Acad Sci USA 1995; 92(5): 1381-5.
27. Engelman JA, Wykoff CC, Yasuhara S, Song KS, Okamoto T, Lisanti MP. Recombinant expression of Caveolin-1 in oncogenically transformed cells abrogates anchorageindependent growth. J Biol Chem 1997; 272(26): 16374-81.
28. Galbiati F, Volonte D, Brown AM, et al. Caveolin-1 expression inhibits Wnt/beta-catenin/Lef-1 signaling by recruiting beta-catenin to caveolae membrane domains. J Biol Chem 2000; 275(30): 23368-77.
29. Racine C, Belanger M, Hirabayashi H, Boucher M, Chakir J, Couet J. Reduction of Caveolin 1 gene expression in lung carcinoma cell lines. Biochem Biophys Res Commun 1999; 255(3): 580-6.
30. Lee SW, Reimer CL, Oh P, Campbell DB, Schnitzer JE. Tumor cell growth inhibition by Caveolin re-expression in human breast cancer cells. Oncogene 1998; 16(11): 1391-7.
31. Bender FC, Reymond MA, Bron C, Quest AF. Caveolin-1 levels are down-regulated in human colon tumors, and ectopic expression of Caveolin-1 in colon carcinoma cell lines reduces cell tumorigenicity. Cancer Res 2000; 60(20): 5870-8.
32. Wiechen K, Diatchenko L, Agoulnik A, et al. Caveolin-1 is down-regulated in human ovarian carcinoma and acts as a candidate tumor suppressor gene. Am J Pathol 2001; 159(5): 1635-43.
33. Capozza F, Williams TM, Schubert W, et al. Absence of Caveolin-1 sensitizes mouse skin to carcinogen-induced epidermal hyperplasia and tumor formation. Am J Pathol 2003; 162(6): 2029-39.
34. Williams TM, Cheung MW, Park DS, et al. Loss of Caveolin-1 gene expression accelerates the development of dysplastic mammary lesions in tumor-prone transgenic mice. Mol Biol Cell 2003; 14(3): 1027-42.
35. Lin MI, Yu J, Murata T, Sessa WC. Caveolin-1-deficient mice have increased tumor microvascular permeability, angiogenesis, and growth. Cancer Res 2007; 67(6): 2849-56.
36. Engelman JA, Lee RJ, Karnezis A, et al. Reciprocal regulation of neu tyrosine kinase activity and Caveolin-1 protein expression in vitro and in vivo. Implications for human breast cancer. J Biol Chem 1998; 273(32): 20448-55.
37. Hayashi K, Matsuda S, Machida K, et al. Invasion activating Caveolin-1 mutation in human scirrhous breast cancers. Cancer Res 2001; 61(6): 2361-4.
38. Lee H, Park DS, Razani B, Russell RG, Pestell RG, Lisanti MP. Caveolin-1 mutations (P132L and null) and the pathogenesis of breast cancer: Caveolin-1 (P132L) behaves in a dominant-negative manner and Caveolin-1 (-/-) null mice show mammary epithelial cell hyperplasia. Am J Pathol 2002; 161(4): 1357-69.
39. Li T, Sotgia F, Vuolo MA, et al. Caveolin-1 mutations in human breast cancer: functional association with estrogen receptor alpha-positive status. Am J Pathol 2006; 168(6): 1998-2013.
40. Luanpitpong S, Talbott SJ, Rojanasakul Y, et al. Regulation of lung cancer cell migration and invasion by reactive oxygen species and Caveolin-1. J Biol Chem 2010; 285(50): 38832-40.
41. Bartz R, Zhou J, Hsieh JT, Ying Y, Li W, Liu P. Caveolin-1 secreting LNCaP cells induce tumor growth of Caveolin-1 negative LNCaP cells in vivo. Int J Cancer 2008; 122(3): 520-5.
42. Karam JA, Lotan Y, Roehrborn CG, Ashfaq R, Karakiewicz PI, Shariat SF. Caveolin-1 overexpression is associated with aggressive prostate cancer recurrence. Prostate 2007; 67(6): 614-22.
43. Yang CP, Galbiati F, Volonte D, Horwitz SB, Lisanti MP. Upregulation of Caveolin-1 and caveolae organelles in Taxolresistant A549 cells. FEBS Lett 1998; 439(3): 368-72.
44. Yang G, Truong LD, Timme TL, et al. Elevated expression of Caveolin is associated with prostate and breast cancer. Clin Cancer Res 1998; 4(8): 1873-80.
45. Li WP, Liu P, Pilcher BK, Anderson RG. Cell-specific targeting of Caveolin-1 to caveolae, secretory vesicles, cytoplasm or mitochondria. J Cell Sci 2001; 114(Pt 7): 1397-408.
46. Tahir SA, Yang G, Ebara S, et al. Secreted Caveolin-1 stimulates cell survival/clonal growth and contributes to metastasis in androgen-insensitive prostate cancer. Cancer Res 2001; 61(10): 3882-5.
47. Lavie Y, Fiucci G, Liscovitch M. Up-regulation of caveolae and caveolar constituents in multidrug-resistant cancer cells. J Biol Chem 1998; 273(49): 32380-3.
48. Fiucci G, Ravid D, Reich R, Liscovitch M. Caveolin-1 inhibits anchorage-independent growth, anoikis and invasiveness in MCF-7 human breast cancer cells. Oncogene 2002; 21(15): 2365-75.
49. Ravid D, Maor S, Werner H, Liscovitch M. Caveolin-1 inhibits anoikis and promotes survival signaling in cancer cells. Adv Enzyme Regul 2006; 46: 163-75.
50. Ando T, Ishiguro H, Kimura M, et al. The overexpression of Caveolin-1 and Caveolin-2 correlates with a poor prognosis and tumor progression in esophageal squamous cell carcinoma. Oncol Rep 2007; 18(3): 601-9.
51. Ho CC, Kuo SH, Huang PH, Huang HY, Yang CH, Yang PC. Caveolin-1 expression is significantly associated with drug resistance and poor prognosis in advanced non-small cell lung cancer patients treated with gemcitabine-based chemotherapy. Lung Cancer 2008; 59(1): 105-10.
52. Savage K, Lambros MB, Robertson D, et al. Caveolin 1 is overexpressed and amplified in a subset of basal-like and metaplastic breast carcinomas: a morphologic, ultrastructural, immunohistochemical, and in situ hybridization analysis. Clin Cancer Res 2007; 13(1): 90-101.
53. Parat MO, Anand-Apte B, Fox PL. Differential Caveolin-1 polarization in endothelial cells during migration in two and three dimensions. Mol Biol Cell 2003; 14(8): 3156-68.
54. Beardsley A, Fang K, Mertz H, Castranova V, Friend S, Liu J. Loss of Caveolin-1 polarity impedes endothelial cell polarization and directional movement. J Biol Chem 2005; 280(5): 3541-7.
55. Santilman V, Baran J, Anand-Apte B, Evans RM, Parat MO. Caveolin-1 polarization in transmigrating endothelial cells requires binding to intermediate filaments. Angiogenesis 2007; 10(4): 297-305.
56. Ho CC, Huang PH, Huang HY, Chen YH, Yang PC, Hsu SM. Up-regulated Caveolin-1 accentuates the metastasis capability of lung adenocarcinoma by inducing filopodia formation. Am J Pathol 2002; 161(5): 1647-56.
57. Lee H, Volonte D, Galbiati F, et al. Constitutive and growth factor-regulated phosphorylation of Caveolin-1 occurs at the same site (Tyr-14) in vivo: identification of a c-Src/Cav- 1/Grb7 signaling cassette. Mol Endocrinol 2000; 14(11): 1750-75.
58. Hatanaka M, Maeda T, Ikemoto T, Mori H, Seya T, Shimizu A. Expression of Caveolin-1 in human T cell leukemia cell lines. Biochem Biophys Res Commun 1998; 253(2): 382-7.
59. Li L, Yang G, Ebara S, et al. Caveolin-1 mediates testosterone-stimulated survival/clonal growth and promotes metastatic activities in prostate cancer cells. Cancer Res 2001; 61(11): 4386-92.
60. Garcia S, Dales JP, Charafe-Jauffret E, et al. Poor prognosis in breast carcinomas correlates with increased expression of targetable CD146 and c-Met and with proteomic basal-like phenotype. Hum Pathol 2007; 38(6): 830-41.
61. Williams TM, Lisanti MP. Caveolin-1 in oncogenic transformation, cancer, and metastasis. Am J Physiol Cell Physiol 2005; 288(3): C494-506.
62. Felley-Bosco E, Bender FC, Courjault-Gautier F, Bron C, Quest AF. Caveolin-1 down-regulates inducible nitric oxide synthase via the proteasome pathway in human colon carcinoma cells. Proc Natl Acad Sci USA 2000; 97(26): 14334-9.
63. Felley-Bosco E, Bender F, Quest AF. Caveolin-1-mediated post-transcriptional regulation of inducible nitric oxide synthase in human colon carcinoma cells. Biol Res 2002; 35(2): 169-76.
64. Mastick CC, Brady MJ, Saltiel AR. Insulin stimulates the tyrosine phosphorylation of Caveolin. J Cell Biol 1995; 129(6): 1523-31.
65. Mastick CC, Saltiel AR. Insulin-stimulated tyrosine phosphorylation of Caveolin is specific for the differentiated adipocyte phenotype in 3T3-L1 cells. J Biol Chem 1997; 272(33): 20706-14.
66. Kimura A, Mora S, Shigematsu S, Pessin JE, Saltiel AR. The insulin receptor catalyzes the tyrosine phosphorylation of Caveolin-1. J Biol Chem 2002; 277(33): 30153-8.
67. Cao H, Courchesne WE, Mastick CC. A phosphotyrosinedependent protein interaction screen reveals a role for phosphorylation of Caveolin-1 on tyrosine 14: recruitment of C-terminal Src kinase. J Biol Chem 2002; 277(11): 8771-4.
68. Cao H, Sanguinetti AR, Mastick CC. Oxidative stress activates both Src-kinases and their negative regulator Csk and induces phosphorylation of two targeting proteins for Csk: Caveolin-1 and paxillin. Exp Cell Res 2004; 294(1): 159-71.
69. Volonte D, Galbiati F, Pestell RG, Lisanti MP. Cellular stress induces the tyrosine phosphorylation of Caveolin-1 (Tyr(14)) via activation of p38 mitogen-activated protein kinase and c- Src kinase. Evidence for caveolae, the actin cytoskeleton, and focal adhesions as mechanical sensors of osmotic stress. J Biol Chem 2001; 276(11): 8094-103.
70. Labrecque L, Nyalendo C, Langlois S, et al. Src-mediated tyrosine phosphorylation of Caveolin-1 induces its association with membrane type 1 matrix metalloproteinase. J Biol Chem 2004; 279(50): 52132-40.
71. del Pozo MA, Balasubramanian N, Alderson NB, et al. Phospho-Caveolin-1 mediates integrin-regulated membrane domain internalization. Nat Cell Biol 2005; 7(9): 901-8.
72. Del Pozo MA, Schwartz MA. Rac, membrane heterogeneity, Caveolin and regulation of growth by integrins. Trends Cell Biol 2007; 17(5): 246-50.
73. Orlichenko L, Huang B, Krueger E, McNiven MA. Epithelial growth factor-induced phosphorylation of Caveolin 1 at tyrosine 14 stimulates caveolae formation in epithelial cells. J Biol Chem 2006; 281(8): 4570-9.
74. Fang PK, Solomon KR, Zhuang L, et al. Caveolin-1alpha and -1beta perform nonredundant roles in early vertebrate development. Am J Pathol 2006; 169(6): 2209-22.
75. Galbiati F, Volonte D, Liu J, et al. Caveolin-1 expression negatively regulates cell cycle progression by inducing G(0)/G(1) arrest via a p53/p21(WAF1/Cip1)-dependent mechanism. Mol Biol Cell 2001; 12(8): 2229-44.
76. Volonte D, Zhang K, Lisanti MP, Galbiati F. Expression of Caveolin-1 induces premature cellular senescence in primary cultures of murine fibroblasts. Mol Biol Cell 2002; 13(7): 2502-17.
77. Dasari A, Bartholomew JN, Volonte D, Galbiati F. Oxidative stress induces premature senescence by stimulating Caveolin-1 gene transcription through p38 mitogen-activated protein kinase/Sp1-mediated activation of two GC-rich promoter elements. Cancer Res 2006; 66(22): 10805-14.
78. Galbiati F, Volonte D, Engelman JA, et al. Targeted downregulation of Caveolin-1 is sufficient to drive cell transformation and hyperactivate the p42/44 MAP kinase cascade. EMBO J 1998; 17(22): 6633-48.
79. Volonte D, Galbiati F, Lisanti MP. Visualization of Caveolin-1, a caveolar marker protein, in living cells using green fluorescent protein (GFP) chimeras. The subcellular distribution of Caveolin-1 is modulated by cell-cell contact. FEBS Lett 1999; 445(2-3): 431-9.
80. Lu Z, Ghosh S, Wang Z, Hunter T. Downregulation of Caveolin-1 function by EGF leads to the loss of E-cadherin, increased transcriptional activity of beta-catenin, and enhanced tumor cell invasion. Cancer Cell 2003; 4(6): 499-515.
81. Torres VA, Tapia JC, Rodriguez DA, et al. Caveolin-1 controls cell proliferation and cell death by suppressing expression of the inhibitor of apoptosis protein survivin. J Cell Sci 2006; 119(Pt 9): 1812-23.
82. Rodriguez DA, Tapia JC, Fernandez JG, et al. Caveolin-1- mediated suppression of cyclooxygenase-2 via a betacatenin- Tcf/Lef-dependent transcriptional mechanism reduced prostaglandin E2 production and survivin expression. Mol Biol Cell 2009; 20(8): 2297-310.
83. Hulit J, Bash T, Fu M, et al. The cyclin D1 gene is transcriptionally repressed by Caveolin-1. J Biol Chem 2000; 275(28): 21203-9.
84. Wang F, Bhat K, Doucette M, et al. Docosahexaenoic acid (DHA) sensitizes brain tumor cells to etoposide-induced apoptosis. Curr Mol Med 2011; 11(6): 503-11.
85. Li J, Hassan GS, Williams TM, et al. Loss of Caveolin-1 causes the hyper-proliferation of intestinal crypt stem cells, with increased sensitivity to whole body gamma-radiation. Cell Cycle 2005; 4(12): 1817-25.
86. Sotgia F, Williams TM, Cohen AW, Minetti C, Pestell RG, Lisanti MP. Caveolin-1-deficient mice have an increased mammary stem cell population with upregulation of Wnt/betacatenin signaling. Cell Cycle 2005; 4(12): 1808-16.
87. Hnasko R, Lisanti MP. The biology of caveolae: lessons from Caveolin knockout mice and implications for human disease. Mol Interv 2003; 3(8): 445-64.
88. Le Lay S, Kurzchalia TV. Getting rid of Caveolins: phenotypes of Caveolin-deficient animals. Biochim Biophys Acta 2005; 1746(3): 322-33.
89. Zhang H, Su L, Muller S, et al. Restoration of Caveolin-1 expression suppresses growth and metastasis of head and neck squamous cell carcinoma. Br J Cancer 2008; 99(10): 1684-94.
90. Gu D, Li H, Wang Z, Chen Q, Jiang J, Zhu H. Caveolin-1 inhibits the growth of human laryngeal squamous cell carcinoma and down regulates EGFR-MAPKs signaling pathway. Laryngoscope 2007; 117(10): 1782-9.
91. Gosens R, Stelmack GL, Dueck G, et al. Role of Caveolin-1 in p42/p44 MAP kinase activation and proliferation of human airway smooth muscle. Am J Physiol Lung Cell Mol Physiol 2006; 291(3): L523-34.
92. Vanhaesebroeck B, Alessi DR. The PI3K-PDK1 connection: more than just a road to PKB. Biochem J 2000; 346(Pt 3): 561-76.
93. Liang J, Slingerland JM. Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression. Cell Cycle 2003; 2(4): 339-45.
94. Cully M, You H, Levine AJ, Mak TW. Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat Rev Cancer 2006; 6(3): 184-92.
95. Vanhaesebroeck B, Vogt PK, Rommel C. PI3K: from the bench to the clinic and back. Curr Top Microbiol Immunol 2010; 347: 1-19.
96. Yu W, Cassara J, Weller PF. Phosphatidylinositide 3-kinase localizes to cytoplasmic lipid bodies in human polymorphonuclear leukocytes and other myeloid-derived cells. Blood 2000; 95(3): 1078-85.
97. Feng S, Wang Y, Wang X, et al. Caveolin-1 gene silencing promotes the activation of PI3K/AKT dependent on Eralpha36 and the transformation of MCF10ACE. Sci China Life Sci 2010; 53(5): 598-605.
98. Xia H, Khalil W, Kahm J, Jessurun J, Kleidon J, Henke CA. Pathologic Caveolin-1 regulation of PTEN in idiopathic pulmonary fibrosis. Am J Pathol 2010; 176(6): 2626-37.
99. Ono K, Iwanaga Y, Hirayama M, Kawamura T, Sowa N, Hasegawa K. Contribution of Caveolin-1 alpha and Akt to TNF-alpha-induced cell death. Am J Physiol Lung Cell Mol Physiol 2004; 287(1): L201-9.
100. Shack S, Wang XT, Kokkonen GC, Gorospe M, Longo DL, Holbrook NJ. Caveolin-induced activation of the phosphatidylinositol 3-kinase/Akt pathway increases arsenite cytotoxicity. Mol Cell Biol 2003; 23(7): 2407-14.
101. Zundel W, Swiersz LM, Giaccia A. Caveolin 1-mediated regulation of receptor tyrosine kinase-associated phosphatidylinositol 3-kinase activity by ceramide. Mol Cell Biol 2000; 20(5): 1507-14.
102. Torres VA, Tapia JC, Rodriguez DA, et al. E-cadherin is required for Caveolin-1-mediated down-regulation of the inhibitor of apoptosis protein survivin via reduced betacatenin-Tcf/Lef-dependent transcription. Mol Cell Biol 2007; 27(21): 7703-17.
103. Shan T, Ma Q, Guo K, et al. Xanthones from mangosteen extracts as natural chemopreventive agents: potential anticancer drugs. Curr Mol Med 2011; 11(8): 666-77.
104. Hellwig CT, Passante E, Rehm M. The molecular machinery regulating apoptosis signal transduction and its implication in human physiology and pathophysiologies. Curr Mol Med 2011; 11(1): 31-47.
105. Zhang W, Yokota H, Xu Z, et al. Hyperoxia Therapy of Preproliferative Ischemic Retinopathy in a Mouse Model. Invest Ophthalmol Vis Sci 2011; 52(9): 6384-95.
106. Ryter SW, Lee SJ, Choi AM. Autophagy in cigarette smokeinduced chronic obstructive pulmonary disease. Expert Rev Respir Med 2010; 4(5): 573-84.
107. Ryter SW, Lam HC, Chen ZH, Choi AM. Deadly triplex: smoke, autophagy and apoptosis. Autophagy 2011; 7(4): 436-7.
108. Zhang XJ, Yang L, Zhao Q, et al. Induction of acetylcholinesterase expression during apoptosis in various cell types. Cell Death Differ 2002; 9(8): 790-800.
109. Jin QH, He HY, Shi YF, Lu H, Zhang XJ. Overexpression of acetylcholinesterase inhibited cell proliferation and promoted apoptosis in NRK cells. Acta Pharmacol Sin 2004; 25(8): 1013-21.
110. Park SE, Jeong SH, Yee SB, et al. Interactions of acetylcholinesterase with Caveolin-1 and subsequently with cytochrome c are required for apoptosome formation. Carcinogenesis 2008; 29(4): 729-37.
111. Henriquez M, Armisen R, Stutzin A, Quest AF. Cell death by necrosis, a regulated way to go. Curr Mol Med 2008; 8(3): 187-206.
112. Gargalovic P, Dory L. Cellular apoptosis is associated with increased Caveolin-1 expression in macrophages. J Lipid Res 2003; 44(9): 1622-32.
113. Yamamoto M, Toya Y, Schwencke C, Lisanti MP, Myers MG, Jr., Ishikawa Y. Caveolin is an activator of insulin receptor signaling. J Biol Chem 1998; 273(41): 26962-8.
114. Galbiati F, Razani B, Lisanti MP. Emerging themes in lipid rafts and caveolae. Cell 2001; 106(4): 403-11.
115. Salani B, Briatore L, Garibaldi S, Cordera R, Maggi D. Caveolin-1 down-regulation inhibits insulin-like growth factor- I receptor signal transduction in H9C2 rat cardiomyoblasts. Endocrinology 2008; 149(2): 461-5.
116. Repetto S, Salani B, Maggi D, Cordera R. Insulin and IGF-I phosphorylate eNOS in HUVECs by a Caveolin-1 dependent mechanism. Biochem Biophys Res Commun 2005; 337(3): 849-52.
117. Li L, Ren CH, Tahir SA, Ren C, Thompson TC. Caveolin-1 maintains activated Akt in prostate cancer cells through scaffolding domain binding site interactions with and inhibition of serine/threonine protein phosphatases PP1 and PP2A. Mol Cell Biol 2003; 23(24): 9389-404.
118. Timme TL, Goltsov A, Tahir S, et al. Caveolin-1 is regulated by c-myc and suppresses c-myc-induced apoptosis. Oncogene 2000; 19(29): 3256-65.
119. Williams TM, Hassan GS, Li J, et al. Caveolin-1 promotes tumor progression in an autochthonous mouse model of prostate cancer: genetic ablation of Cav-1 delays advanced prostate tumor development in tramp mice. J Biol Chem 2005; 280(26): 25134-45.
120. Zhang X, Ling MT, Wang Q, et al. Identification of a novel inhibitor of differentiation-1 (ID-1) binding partner, Caveolin- 1, and its role in epithelial-mesenchymal transition and resistance to apoptosis in prostate cancer cells. J Biol Chem 2007; 282(46): 33284-94.
121. Head BP, Patel HH, Tsutsumi YM, et al. Caveolin-1 expression is essential for N-methyl-D-aspartate receptormediated Src and extracellular signal-regulated kinase 1/2 activation and protection of primary neurons from ischemic cell death. FASEB J 2008; 22(3): 828-40.
122. Barzan D, Maier P, Zeller WJ, Wenz F, Herskind C. Overexpression of Caveolin-1 in lymphoblastoid TK6 cells enhances proliferation after irradiation with clinically relevant doses. Strahlenther Onkol 2010; 186(2): 99-106.
123. Cordes N, Frick S, Brunner TB, et al. Human pancreatic tumor cells are sensitized to ionizing radiation by knockdown of Caveolin-1. Oncogene 2007; 26(48): 6851-62.
124. Chanvorachote P, Nimmannit U, Lu Y, Talbott S, Jiang BH, Rojanasakul Y. Nitric oxide regulates lung carcinoma cell anoikis through inhibition of ubiquitin-proteasomal degradation of Caveolin-1. J Biol Chem 2009; 284(41): 28476-84.
125. Tang Y, Zeng X, He F, Liao Y, Qian N, Toi M. Caveolin-1 is related to invasion, survival, and poor prognosis in hepatocellular cancer. Med Oncol 2012; 29(2): 977-84.
126. Zhang Z, Yao K, Jin C. Apoptosis of lens epithelial cells induced by high concentration of glucose is associated with a decrease in Caveolin-1 levels. Mol Vis 2009; 15: 2008-17.
127. Shen J, Lee W, Li Y, et al. Interaction of Caveolin-1, nitric oxide, and nitric oxide synthases in hypoxic human SK-N-MC neuroblastoma cells. J Neurochem 2008; 107(2): 478-87.
128. Senou M, Costa MJ, Massart C, et al. Role of Caveolin-1 in thyroid phenotype, cell homeostasis, and hormone synthesis: in vivo study of Caveolin-1 knockout mice. Am J Physiol Endocrinol Metab 2009; 297(2): E438-51.
129. Jasmin JF, Malhotra S, Singh Dhallu M, Mercier I, Rosenbaum DM, Lisanti MP. Caveolin-1 deficiency increases cerebral ischemic injury. Circ Res 2007; 100(5): 721-9.
130. Wu CP, Calcagno AM, Ambudkar SV. Reversal of ABC drug transporter-mediated multidrug resistance in cancer cells: evaluation of current strategies. Curr Mol Pharmacol 2008; 1(2): 93-105.
131. Moon KC, Lee GK, Yoo SH, et al. Expression of Caveolin-1 in pleomorphic carcinoma of the lung is correlated with a poor prognosis. Anticancer Res 2005; 25(6C): 4631-7.
132. Suzuoki M, Miyamoto M, Kato K, et al. Impact of Caveolin-1 expression on prognosis of pancreatic ductal adenocarcinoma. Br J Cancer 2002; 87(10): 1140-4.
133. Campbell L, Gumbleton M, Griffiths DF. Caveolin-1 overexpression predicts poor disease-free survival of patients with clinically confined renal cell carcinoma. Br J Cancer 2003; 89(10): 1909-13.
134. Selga E, Morales C, Noe V, Peinado MA, Ciudad CJ. Role of Caveolin 1, E-cadherin, Enolase 2 and PKCalpha on resistance to methotrexate in human HT29 colon cancer cells. BMC Med Genomics 2008; 1: 35.
135. Belanger MM, Gaudreau M, Roussel E, Couet J. Role of Caveolin-1 in etoposide resistance development in A549 lung cancer cells. Cancer Biol Ther 2004; 3(10): 954-9.
136. Linge A, Morishima N, Kasper M, Barth K. Bleomycin induces Caveolin-1 and -2 expression in epithelial lung cancer A549 cells. Anticancer Res 2007; 27(3A): 1343-51.
137. Tirado OM, MacCarthy CM, Fatima N, Villar J, Mateo-Lozano S, Notario V. Caveolin-1 promotes resistance to chemotherapy-induced apoptosis in Ewing's sarcoma cells by modulating PKCalpha phosphorylation. Int J Cancer 2010; 126(2): 426-36.
138. Thompson TC, Timme TL, Li L, Goltsov A. Caveolin-1, a metastasis-related gene that promotes cell survival in prostate cancer. Apoptosis 1999; 4(4): 233-7.
139. Nasu Y, Timme TL, Yang G, et al. Suppression of Caveolin expression induces androgen sensitivity in metastatic androgen-insensitive mouse prostate cancer cells. Nat Med 1998; 4(9): 1062-4.
140. Katsogiannou M, El Boustany C, Gackiere F, et al. Caveolae contribute to the apoptosis resistance induced by the alpha(1A)-adrenoceptor in androgen-independent prostate cancer cells. PLoS One 2009; 4(9): e7068.
141. Park J, Bae E, Lee C, et al. RNA interference-directed Caveolin-1 knockdown sensitizes SN12CPM6 cells to doxorubicin-induced apoptosis and reduces lung metastasis. Tumour Biol 2010; 31(6): 643-50.
142. Herzog M, Storch CH, Gut P, et al. Knockdown of Caveolin-1 decreases activity of breast cancer resistance protein (BCRP/ABCG2) and increases chemotherapeutic sensitivity. Naunyn Schmiedebergs Arch Pharmacol 2010; 383(1): 1-11.
143. Demeule M, Jodoin J, Gingras D, Beliveau R. P-glycoprotein is localized in caveolae in resistant cells and in brain capillaries. FEBS Lett 2000; 466(2-3): 219-24.
144. Barakat S, Demeule M, Pilorget A, et al. Modulation of pglycoprotein function by Caveolin-1 phosphorylation. J Neurochem 2007; 101(1): 1-8.
145. Cai C, Chen J. Overexpression of Caveolin-1 induces alteration of multidrug resistance in Hs578T breast adenocarcinoma cells. Int J Cancer 2004; 111(4): 522-9.
146. Pang A, Au WY, Kwong YL. Caveolin-1 gene is coordinately regulated with the multidrug resistance 1 gene in normal and leukemic bone marrow. Leuk Res 2004; 28(9): 973-7.
147. Belanger MM, Roussel E, Couet J. Caveolin-1 is downregulated in human lung carcinoma and acts as a candidate tumor suppressor gene. Chest 2004; 125(5 Suppl): 106S.
148. Storch CH, Ehehalt R, Haefeli WE, Weiss J. Localization of the human breast cancer resistance protein (BCRP/ABCG2) in lipid rafts/caveolae and modulation of its activity by cholesterol in vitro. J Pharmacol Exp Ther 2007; 323(1): 257-64.
149. Liu J, Lee P, Galbiati F, Kitsis RN, Lisanti MP. Caveolin-1 expression sensitizes fibroblastic and epithelial cells to apoptotic stimulation. Am J Physiol Cell Physiol 2001; 280(4): C823-35.
150. Zhang M, Lin L, Lee SJ, et al. Deletion of Caveolin-1 protects hyperoxia-induced apoptosis via survivin-mediated pathways. Am J Physiol Lung Cell Mol Physiol 2009; 297(5): L945-53.